research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
Search
for
Sort by
Research
60-90 / 1000+ results
research First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
research Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia
Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer
Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
research Epigallocatechin-3-gallate inhibits paclitaxel-induced apoptosis through the alteration of microRNA expression in human dermal papilla cells
Green tea extract helps prevent cell death and supports cell survival in hair cells exposed to a chemotherapy drug.
research Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
research TICE salvage chemotherapy treats germ-cell tumors effectively
TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
research Paclitaxel/Platinum combination regimen and alopecia
Most patients experienced significant but reversible hair loss during treatment.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment
Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research 506 Taxane chemotherapy promotes aging of human hair follicles and their stem cells
Paclitaxel chemotherapy causes premature aging and damage to hair follicles, potentially leading to permanent hair loss.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity
A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
research Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
The combination therapy is effective and well-tolerated for treating esophageal cancer.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
The study investigated the toxicity profile and pharmacokinetics of Doxil in 45 patients with metastatic breast carcinoma, previously treated with chemotherapy. Six different dose schedules were tested, and pharmacokinetics were examined in 24 patients. Results showed that stomatitis and skin toxicity (PPE) were dose and schedule dependent, with higher doses and shorter intervals increasing severity. Myelosuppression was mild, and hair loss was infrequent. Cardiac toxicity was rare, occurring in only 1 patient. Doxil demonstrated significant antitumor activity, with objective responses in 9 patients. Pharmacokinetics showed a long half-life and linear increase in Cmax and AUC with dose. Toxicity correlated with pharmacokinetic parameters, suggesting that pharmacokinetic guidance could optimize Doxil dosing.
research 803 Taxane chemotherapy induces epigenetic changes and premature senescence in human scalp hair follicles
Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research Mechanism-Based Strategies for Prevention of Taxane-Induced Hair Follicle Damage in Cancer Chemotherapy
Low-intensity ultrasound may prevent hair loss during taxane chemotherapy.
research EXPERIENCE OF A PRIVATE HOSPITAL IN THE FEDERAL DISTRICT IN CRYOTHERAPY WITH A HYPOTHERMAL CAP FOR PATIENTS USING PACLITAXEL 80 MG/M² WEEKLY FOR 12 WEEKS
Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
research Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab Paclitaxel
Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
research Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
St. John's wort skin oil may increase skin damage risk during radiotherapy.
research An overview of management of drug-induced hair and nail disorders
Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.